AllianceBernstein’s Clovis Oncology, Inc. CLVS Stock Holding History

AllianceBernstein’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-166,500	Closed	-$336K	–	3449
2022 Q1	$336K	Buy	166,500 +700	+0.4%	+$1.38K	﹤0.01%	2838
2021 Q4	$449K	Sell	165,800 -200,000	-55%	-$739K	﹤0.01%	2791
2021 Q3	$1.63M	Buy	365,800 +146,900	+67%	+$708K	﹤0.01%	2273
2021 Q2	$1.27M	Buy	218,900 +134,600	+160%	+$789K	﹤0.01%	2432
2021 Q1	$592K	Hold	84,300	–	–	﹤0.01%	2603
2020 Q4	$405K	Sell	84,300 -9,800	-10%	-$49.6K	﹤0.01%	2691
2020 Q3	$549K	Sell	94,100 -35,600	-27%	-$213K	﹤0.01%	2477
2020 Q2	$875K	Buy	129,700 +47,800	+58%	+$362K	﹤0.01%	2273
2020 Q1	$521K	Buy	81,900 +10,900	+15%	+$87.4K	﹤0.01%	2335
2019 Q4	$740K	Sell	71,000 -12,140	-15%	-$88.3K	﹤0.01%	2401
2019 Q3	$327K	Buy	83,140 +14,100	+20%	+$114K	﹤0.01%	2775
2019 Q2	$1.03M	Sell	69,040 -123,300	-64%	-$2.23M	﹤0.01%	2302
2019 Q1	$4.77M	Sell	192,340 -226,700	-54%	-$5.68M	﹤0.01%	1406
2018 Q4	$7.53M	Sell	419,040 -995,612	-70%	-$20.3M	0.01%	1112
2018 Q3	$41.5M	Buy	1,414,652 +461,629	+48%	+$17.9M	0.03%	591
2018 Q2	$43.3M	Sell	953,023 -224,954	-19%	-$10.9M	0.03%	564
2018 Q1	$62.2M	Buy	1,177,977 +175,080	+17%	+$10.2M	0.05%	431
2017 Q4	$68.2M	Buy	1,002,897 +41,120	+4%	+$2.87M	0.05%	415
2017 Q3	$79.3M	Buy	961,777 +3,056	+0.3%	+$242K	0.06%	359
2017 Q2	$89.8M	Buy	958,721 +204,599	+27%	+$12.5M	0.07%	311
2017 Q1	$48M	Buy	754,122 +708,082	+1,538%	+$43M	0.04%	486
2016 Q4	$2.04M	Hold	46,040	–	–	﹤0.01%	1823
2016 Q3	$1.66M	Sell	46,040 -300	-0.6%	-$6.44K	﹤0.01%	1909
2016 Q2	$636K	Hold	46,340	–	–	﹤0.01%	2416
2016 Q1	$890K	Hold	46,340	–	–	﹤0.01%	2166
2015 Q4	$1.62M	Hold	46,340	–	–	﹤0.01%	1794
2015 Q3	$4.26M	Buy	46,340 +140	+0.3%	+$12.1K	﹤0.01%	1125
2015 Q2	$4.06M	Hold	46,200	–	–	﹤0.01%	1226
2015 Q1	$3.43M	Sell	46,200 -500	-1%	-$35.3K	﹤0.01%	1344
2014 Q4	$2.62M	Buy	46,700 +1,800	+4%	+$94.6K	﹤0.01%	1544
2014 Q3	$2.04M	Buy	44,900 +700	+2%	+$29.2K	﹤0.01%	1701
2014 Q2	$1.83M	Buy	44,200 +8,000	+22%	+$412K	﹤0.01%	1836
2014 Q1	$2.51M	Buy	36,200 +1,900	+6%	+$140K	﹤0.01%	1538
2013 Q4	$2.07M	Sell	34,300 -430,398	-93%	-$23.4M	﹤0.01%	1682
2013 Q3	$28.2M	Buy	464,698 +116,296	+33%	+$8.25M	0.03%	570
2013 Q2	$23.3M	Buy	+348,402	New	+$15.7M	0.02%	605

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

AllianceBernstein's CLVS Position: Q2 2022 in Review

AllianceBernstein sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 166,500 shares — an estimated $336K sold.

AllianceBernstein first reported a position in CLVS in Q2 2013 and held it in 36 quarters. The position peaked at $89.8M in Q2 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

AllianceBernstein reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
AllianceBernstein sold 166,500 Clovis Oncology, Inc. shares in Q2 2022, an estimated $336K.
AllianceBernstein first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 36 quarters.
AllianceBernstein's Clovis Oncology, Inc. position peaked at $89.8M in Q2 2017.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.